Repligen | RGEN - Assets


Repligen reported $2.95B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Agilent USD 12.81B 86M Dec/2025
Align Technology USD 6.23B 141K Dec/2025
Bio Techne USD 2.52B 3.45M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Bruker USD 6.24B 193.5M Dec/2025
Charles River Laboratories USD 7.14B 378.39M Dec/2025
Danaher USD 83.46B 3.57B Dec/2025
Dentsply International USD 5.43B 224M Dec/2025
Exact Sciences USD 5.86B 39.38M Dec/2025
General Electric Aerospace USD 130.17B 1.93B Dec/2025
Henry Schein USD 11.22B 118M Dec/2025
Illumina USD 6.64B 467M Dec/2025
IQVIA Holdings USD 29.94B 1.22B Dec/2025
Mettler Toledo International USD 3.71B 191.18M Dec/2025
Myriad Genetics USD 728.1M 50.8M Sep/2025
OraSure Technologies USD 423.1M 21.94M Sep/2025
Pacific Biosciences Of California USD 803.16M 22.31M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Repligen USD 2.95B 25.99M Dec/2025
Revvity USD 12.17B 29.46M Dec/2025
Standard Biotools USD 539.64M 17.32M Sep/2025
Thermo Fisher Scientific USD 110.34B 7.32B Dec/2025
Waters USD 5.08B 221.41M Dec/2025
West Pharmaceutical Services USD 4.27B 164.2M Dec/2025